North Adelaide
North Adelaide
North Adelaide, Australia10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06052267 | |
| Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Peroxisomal Disorders, X-linked disease, adrenal gland disorder, adrenocortical insufficiency, adrenoleukodystrophy, brain disorder, central nervous system disorder, demyelinating disease, endocrine system disorder, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, metabolic disease, nervous system disorder | Active, not recruiting | Not stated | 2026-09-14 | NCT02698579 | |
| A Study of Sepiapterin in Participants With Phenylketonuria (PKU) | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, hereditary disease, inborn disorder of amino acid metabolism, inborn errors of metabolism, metabolic disease, nervous system disorder, phenylketonuria | Recruiting | Phase 3 | 2026-08-28 | NCT06302348 | |
| Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07590934 | |
| A Prospective Natural History Study in Uveal Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Active, not recruiting | Not stated | 2026-08-11 | NCT04588662 | |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-07-21 | NCT06520345 | |
| Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-05-28 | NCT05422222 | |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Noonan syndrome 5, low grade glioma | Active, not recruiting | Phase 3 | 2026-05-14 | NCT05566795 | |
| Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Enrolling by invitation | Phase 3 | 2026-04-29 | NCT05844449 | |
| Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2025-01-27 | NCT05348577 |